This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC.

ACKNOWLEDGEMENT

This educational activity is supported by an educational grant from GlaxoSmithKline.

DATE OF RELEASE/EXPIRATION

This activity was released on November 22, 2022 and is valid until May 22, 2023. Requests for credit must be made no later than May 22, 2023.

TARGET AUDIENCE

The educational design of this activity addresses the needs of medical oncologists, gynecologic oncologists, OB/GYNs, pathologists, nurse practitioners, physician assistants, oncology nurses, and other HCPs involved in the care of patients with endometrial cancer.

STATEMENT OF NEED/PROGRAM OVERVIEW

The treatment landscape for endometrial cancer is evolving, with increasing use of histology/molecular testing-based treatment approaches that differentiate tumors with or without microsatellite instability-high (MSI-H) and mismatch repair deficiency (dMMR). For therapies to be effective, clinicians must identify those patients most likely to benefit from a specific treatment and select the option best suited to each individual patient. To ensure that all patients with endometrial cancer benefit equitably from these treatment advances, it is crucial that barriers to care be addressed appropriately.

In this activity, Dr. Gottfried Konecny will analyze the latest clinical evidence on treatment options for recurrent endometrial cancer. Dr. Konecny will review strategies for personalizing treatment selection with biomarker testing and explore approaches for sequencing therapy and minimizing adverse events. Factors that lead to disparities in treatment will be discussed and strategies to minimize those inequities and improve patient outcomes and quality of life will be presented.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Discuss strategies to reduce disparities in care and improve patient QoL
• Evaluate the relevance of histology and molecular testing to facilitate treatment decision‐ making for second‐line treatment of patients with endometrial cancer
• Assess clinical‐trial evidence on new and practice‐changing therapies for the management of recurrent endometrial cancer
• Evaluate strategies to monitor treatment‐emergent adverse events associated with current and emerging treatment regimens

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.5 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 30 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter	Reported Financial Relationship
Gottfried E. Konecny, MD Professor of Medicine and Ob/Gyn Medical Gynecologic Oncology University of California, Los Angeles	Speakers’ Bureau: AstraZeneca, Clovis, GlaxoSmithKline, Merck

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager	Reported Financial Relationship
Lindsay Borvansky	Nothing to disclose
Andrea Funk	Nothing to disclose
Liddy Knight	Nothing to disclose
Ashley Cann	Nothing to disclose
Lauren Sinclair	Nothing to disclose
Tariqa Ackbarali	Nothing to disclose
Vandana Gupta	Nothing to disclose
Alissa Yost	Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.